Is class III β-tubulin a true predictive marker of sensitivity to vinorelbine in non-small cell lung cancer? Chemosensitivity data evidence

Anticancer Research

Volumn 31, Issue 3, 2011, Pages 999-1005

  Hirai, Yoshimitsu ^a   Yoshimasu, Tatsuya ^a   Oura, Shoji ^a   Ota, Fuminori ^a   Naito, Koma ^a   Nishiguchi, Haruka ^a   Hashimoto, Sayoko ^a   Okamura, Yoshitaka ^a  

^a WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

Class III tubulin; Histoculture drug response assay; Non small cell lung cancer; Predictive marker; Vinorelbine

Indexed keywords

BETA TUBULIN; BETA TUBULIN 3; BIOLOGICAL MARKER; NAVELBINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; CHEMOSENSITIVITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INHIBITION; DRUG RESPONSE; DRUG SENSITIVITY; FEMALE; HISTOCULTURE DRUG RESPONSE ASSAY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; TUBULIN; VINBLASTINE;

EID: 79956115415     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ferlay J, Bray F, Pisani P et al: GLOBOCAN 2000: Cancer Incidence, Mortality and Prevelance Worldwide, Version 1.0. Lyon, France, IARC Press, 2001.
2. Le Chevalier T et al: Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): cisplatin-based chemotherapy (CT) versus no CT in 1867 patients with resected non-small cell lung cancer. Proc Am Soc ClinOncol 22: 2, 2003.
3. Arriagada R, Bergman B et al: Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: The International Adjuvant Lung Cancer Trial (IALT) Collaborative Group. N Engl J Med 350: 351-360, 2004. (Pubitemid 38101630)
4. Kato H, Ichinose Y, Ohta M et al: A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 350: 1713-1721, 2004. (Pubitemid 38501140)
5. Winton T, Livingston R, Johnson D et al: Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med 352: 2589-2597, 2005.
6. Strauss GM, Herndon JE, Maddaus MA et al: Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633. J Clin Oncol 22: 621, 2004.
7. Douillard JY, Rosell R, De Lena M et al: Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomized controlled trial. Lancet Oncology 7: 719-727, 2006.
8. Schiller JH, Harrington D, Belani CP et al: Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98, 2002. (Pubitemid 34438899)
9. Sève P, Lai R, Ding K et al: Class III beta tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC BR.10. Clin Cancer Res 13: 983-991, 2007.
10. Sève P, Isaac S, Tredan O et al: Expression of class III beta-tubulin is predictive of patient outcome in patients with non- small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Caner Res 11: 5481-5486, 2005. (Pubitemid 41060824)
11. Park JG, Kramer BS, Steinberg SM et al: Chemosensitivity testing of human colorectal carcinoma cell lines using tetrazolium-based colorimetric assay. Cancer Res 47: 5875-5879, 1982.
12. Kobayashi H: Collagen gel droplet culture method to examine in vitro chemosensitivity. Method Mol Med 110: 59-67, 2005.
13. Kobayashi H: Development of a new in vitro chemosensitivity test using collagen gel droplet embedded culture and image analysis for clinical usefulness. Recent Results Cancer Res 161: 48-61, 2003.
14. Kubota T, Sasano N, Abe O et al: The potential of the histoculture drug response assay to contribute to cancer patient survival. Clin Cancer Res 1: 1537-1543, 1995. (Pubitemid 26028089)
15. Furukawa T, Kubota T and Hoffman RM: Clinical applications of the histoculture drug response assay. Clin Cancer Res 1: 305-311, 1995.
16. Ohie S, Udagawa Y, Aoki D et al: Histoculture Drug response assay to monitor chemoresponse. Methods Mol Med 110: 79-86, 2005.
17. Yoshimasu T, Oura S, Hirai I et al: Data acquisition for the histoculture drug response aasay in lung cancer. J Thorac Cardiovasc Surg 133: 303-308, 2007. (Pubitemid 46136244)
18. Yoshimasu T, Ohta F, Oura S, Tamaki T, Shimizu Y, Naito K, Kiyoi M, Hirai Y, Kawago M and Okamura Y: Histoculture drug response assay for gefitinib in non-small cell lung cancer. Gen Thorac Cardiovasc Surg 57: 138-143, 2009.
19. Yoshimasu T, Oura S, Hirai I, Tamaki T, Kokawa Y, Ota F, Nakamura R, Shimizu Y, Kawago M, Hirai Y, Naito K, Kiyoi M, Tanino H, Okamura Y and Furukawa T: In vitro evaluation of dose-response curve for paclitaxel in breast cancer. Breast Cancer 14: 401-405, 2007.
20. Akaike H: Inforrmation theory and an extension of the maximum likelihood principle. In: Second International Symposium on Information Theory. Petrov BN and Csaki H (eds.). Budapest: Akademiai Kaido, pp. 267-281, 1973.
21. MacCarty KS Jr., Szabo E, Flowers JL et al: Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46: 4244-4248, 1986.
22. Veronesi A, Crivellari D, Magri MD, Cartei G, Mansutti M, Foladore S and Monfardini S: Vinorelbine treatment of advanced non-small cell lung cancer with special emphasis on elderly patients. Eur J Cancer 32: 1809-1811, 1996.
23. Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P and Dalphin JC: A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 14: 115-119, 1991.
24. Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, Nishiwaki Y, Niitani H and Sakuma A: A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untreated advanced non-small cell lung cancer. Japan Vinorelbine Lung Cancer Study Group. Lung Cancer 11: 385-391, 1994.
25. Dumontet C and Sikic BI: Mechanisms of action of and resistance to antitubulin agents: microtuble dynamics, drug transport, and cell death. J ClinOncol 17: 1061-1070, 1999. (Pubitemid 29109340)
26. Hirai Y, Yoshimasu T, Oura S, Tamaki T, Ota F, Nakamura R, Shimizu Y, Naito K, Ota M, Miyasaka M, Okamura Y, Nakamura Y, Yasuoka H and Kodama R: Histoculture drug response assay guided adjuvant chemotherapy in patients with ERCC1-positive non-small cell lung cancer. Gan To Kagaku Ryoho 36: 611-614, 2009 (in Japanese).
27. Hayashi Y, Kuriyama H, Umezu H, Tanaka J, Yoshimasu T, Furukawa T, Tanaka H, Kagamu H, Geiyo F and Yoshizawa H: class III β-tubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-small cell lung cancer. Inter Med 48: 203-208, 2009.